摘要
目的观察乌司他丁联合低分子肝素早期治疗急性呼吸窘迫综合征（ARDS）的疗效。方法35例ARDS患者随机分为对照组16例和乌司他丁联合低分子肝素治疗组19例，观察两组患者治疗前后肿瘤坏死因子（TNF-α）、白细胞介素-1β、血气分析指标、凝血功能、D-二聚体及血小板的变化，记录机械通气时间及死亡例数。结果随着治疗时间延长，治疗组TNF-α、IL-1β下降较对照组明显（P〈0．05）；治疗组D-二聚体的下降较对照组明显（P〈0．05）；治疗组机械通气时间较对照组明显缩短（P〈0．05）。结论乌司他丁与低分子肝素联合应用，可明显改善ARDS患者的凝血异常，减轻炎症反应，缩短机械通气时间。
Objective To study the curative effects of ulinastatin and early low molecular weight heparin in the treatment of acute respiratory distress syndrome （ ARDS ）. Methods 35 ARDS patients were randomly divided into control group （ 16 cases） and the treatment group （ulinastatin and low molecular weight heparin, 19 cases）. Tumor necrosis factor （ TNF ） - α, IL - 1β, blood gas analysis indexes, coagulation, D -dimer, the platelet changes, mechanical ventilation time, mortality were observed in two groups before and after the treatment. Results With the long - time treatment, TNF - α, IL - 1β and D - dimer decreased significantly in the treatment group than in the control group, the difference was statis- tically significant （ P 〈 0.05 ） ; Mechanical ventilation time was significantly shorter than in the control group, the difference was statistically significant （ P 〈 0.05 ）. Conclusion Ulinastatin and low molecular weight heparin can significantly improve the ARDS patients with abnormal coagulation, reduce inflammation and shorten the time of mechanical ventilation.
出处
《中国急救医学》
CAS
CSCD
北大核心
2009年第5期419-421,共3页
Chinese Journal of Critical Care Medicine
关键词
乌司他丁
低分子肝素
急性呼吸窘迫综合征
Ulinastatin
Low molecular weight heparin
Acute respiratory distress syndrome
